Included in analysis at birth: n=53
Matched maternal and infant blood samples for placental transfer calculations: n= 52
Included in analysis at 2 months: n= 70
Included in analysis at 5 months: n= 65
Included in analysis at 13 months: n= 63
Excluded from analysis if insufficient sample volume

Infants born to DTaP-IPV vaccinated mothers (n=79; includes 2 sets of twins)
Followed up at 2 months: n= 74
Followed up at 3 months: n= 70
Followed up at 4 months: n= 69
Followed up at 5 months: n=67
Followed up at 12 months: 65
Followed up at 13 months: n= 63
Lost to follow-up (n=16): (Did not return for study visits, moved away from area or vaccines given by primary care provider)

Included in analysis at birth: n=57
Matched maternal and infant blood samples for placental transfer calculations: n= 52
Included in analysis at 2 months: n= 62
Included in analysis at 5 months: n= 62
Included in analysis at 13 months: n= 61
Excluded from analysis if insufficient sample volume

Followed up at 2 months: n= 70
Followed up at 3 months: n= 63
Followed up at 4 months: n= 63
Followed up at 5 months: n=63
Followed up at 12 months: 61
Followed up at 13 months: n= 61
Lost to follow-up (n= 19): (Did not return for study visits, moved away from area or vaccines given by primary care provider)

Randomized (n= 154)
Non-randomized control group of women enrolled postnatally (n= 44, of which 19 from Infanrix hexa study)
47 infants born to 45 women (2 sets of twins)

Randomization
Allocation
Follow-Up
Analysis